May 04, 2026
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
May 03, 2026
mRNA medicine and spatiotemporal drug delivery systems are expanding options for cardiovascular disease. The sources describe preclinical proof-of-concept, clinical trials and programmable cardiac repair platforms.
Apr 23, 2026
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
Apr 22, 2026
Peptris has raised INR 70 crore ($7.7 million) in a Series A round to advance programs toward clinical readiness and expand its AI-led drug discovery pipeline over 24 months.
Apr 16, 2026
A new Cochrane review said anti-amyloid Alzheimer’s drugs show no clinically meaningful benefit, but many researchers said the analysis has major limitations. Newer evidence on lecanemab and donanemab and broader drug development efforts continue to shape the field.
Apr 09, 2026
A human study found that epoxy-oxylipins help regulate inflammation and that GSK2256294 increased these molecules, reduced pain faster and lowered intermediate monocytes. The findings map epoxy-oxylipin activity in humans during inflammation.
Apr 07, 2026
The cell surface markers detection market is projected to grow from $7.01 billion in 2026 to $13.33 billion by 2034, driven by increasing adoption of flow cytometry and applications in immunotherapy research. The market serves pharmaceutical, biotechnology, academic, and clinical research organizations through various workflow stages including sample preparation and cell analysis.
Mar 30, 2026
New research reveals that ultra-marathon running damages red blood cells, making them less flexible and accelerating their breakdown. The study found this damage increases with race distance and could potentially lead to anemia. The findings may also help improve blood storage practices for medical transfusions.
Mar 18, 2026
The FDA issued a complete response letter rejecting Aldeyra Therapeutics' reproxalap for dry eye disease, marking the third rejection in three years due to inconsistent trial results and lack of substantial evidence of efficacy.
Mar 17, 2026
A redesigned CD40 agonist antibody achieved complete remission in two of 12 patients with metastatic cancer in early trials, while separate research identified a method to prevent deadly heart complications from immune checkpoint inhibitors.
Mar 05, 2026
Altimmune's pemvidutide received FDA Breakthrough Therapy Designation for MASH treatment, with Phase 3 trial initiation planned for 2026. The company raised $75 million in January 2026 to fund development.
Mar 04, 2026
Can-Fite BioPharma's drug candidate namodenoson met its primary endpoint in a Phase 2a pancreatic cancer trial and demonstrated anti-obesity effects in a peer-reviewed preclinical study published in the International Journal of Obesity.
Mar 04, 2026
At least 111 substances of unknown safety have been added to U.S. foods, drinks and supplements without alerting the FDA, exploiting a legal loophole in the "generally recognized as safe" standard, according to a new investigation.
Mar 03, 2026
Actor James Van Der Beek died at age 48 from colorectal cancer, highlighting a troubling trend of rising cancer rates and deaths among younger Americans despite overall declines in older populations.
Mar 02, 2026
Recent studies examine biological factors affecting sleep in older adults, finding connections between inflammatory markers, antioxidant capacity, and sleep quality in aging populations.
Mar 01, 2026
Anbio Biotechnology shares gained following an upgrade from a sell rating to hold. The company reported $0.04 earnings per share and $2.29 million in quarterly revenue.
Feb 28, 2026
A 30-year study of nearly 200,000 adults found that diet quality matters more than macronutrient ratios for heart health, with both healthy low-carb and low-fat diets reducing coronary heart disease risk equally.
Feb 26, 2026
Researchers at UC San Francisco discovered that exercise triggers liver production of GPLD1, which removes TNAP protein buildup from blood-brain barrier cells, reducing age-related leakiness and cognitive decline.
Feb 13, 2026
MoonLake Immunotherapeutics announced positive topline results from its Phase 2 S-OLARIS trial of sonelokimab in axial spondyloarthritis, with 81% of patients achieving ASAS40 response by Week 12. The company ended Q4 2025 with $394 million in cash.
Feb 13, 2026
Scientists at Northwestern University developed human spinal cord organoids that accurately replicate injury responses including cell death, inflammation, and glial scarring. Testing showed a "dancing molecules" therapy significantly reduced scarring and promoted nerve regrowth.